PW Medtech Group Limited provided earnings guidance for the year ended December 31, 2023. The Group is expected to record (i) a net profit in the range of RMB 192 million to RMB 215 million for the year ended December 31, 2023, representing an increase of 49% to 67% as compared to that of approximately RMB129 million for the year ended December 31, 2022, and (ii) a profit attributable to owners of the Company in the range of RMB 142 million to RMB 165 million for the year ended December 31, 2023, representing an increase of 33% to 55% as compared to that of approximately RMB 106 million for the year ended December 31, 2022. Such increase is primarily due to a significant increase in the profit contributed by the Group's blood purification business and the infusion set business.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.95 HKD | +1.06% | 0.00% | +15.85% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+15.85% | 190M | |
+11.40% | 27.92B | |
-30.75% | 3.08B | |
-15.97% | 2.53B | |
+18.11% | 2.47B | |
+7.78% | 2.1B | |
-9.47% | 1.91B | |
-0.56% | 1.51B | |
+2.24% | 1.34B | |
+24.32% | 1.24B |
- Stock Market
- Equities
- 1358 Stock
- News PW Medtech Group Limited
- PW Medtech Group Limited Provides Earnings Guidance for the Year Ended December 31, 2023